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ABSTRACT 
Diazoxide is an ATP-sensitive potassium channel (KATP) agonist that has been shown to neuroprotective 
effects. These observations raise the possibility that diazoxide may have potential as a therapeutic agent for 
other applications. This study investigated (1) the long term effects of chronic neonatal administration of 
diazoxide and (2) the role of KATP on murin behavior and neurohistology. C57B/6J pups were injected daily 
with diazoxide (10, 20 or 50 mg kg
-1) or vehicle from Postnatal days 2 (P2) through P12. Pups were allow to 
mature  and  underwent  behavioral  testing  at  5-7  months  of  age.  After  behavioral  testing,  animals  were 
euthanized and morphology of the brains was assessed. No long term adverse effects of neonatal diazoxide 
therapy on physical characteristics, visual acuity, sensori-motor reflexes, spontaneous locomotor activity, 
motor coordination/balance or motor learning and memory were observed. In addition, no morphological 
changes were observed on brains. However, we did observe that diazoxide therapy causes depressive-like 
phenotypes  in  female  murine  mice.  Chronic  neonatal  diazoxide  therapy  does  not  cause  deficits  or 
enhancements  in  mice  behavior.  Diazoxide  does  not  cause  abnormal  morphological  changes  in  brain 
anatomy. However, diazoxide does cause gender specific depressive-like phenotype in mice.  
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1. INTRODUCTION 
ATP-sensitive  potassium  (KATP)  channels  are 
expressed  in  a  variety  of  cell  types  including  neurons, 
astrocytes and vascular endothelial cells. In addition, KATP 
channels  have  been  shown  to  regulate  numerous 
physiological  processes  (Ashcroft  and  Ashcroft,  1990). 
Much  attention  has  been  focused  on  the  potential 
therapeutic  function  of  KATP  channels-to  preserve  the 
viability cells or impede cell death in various experimental 
models.  Specifically,  pharmacological  activation  of  the 
mitoKATP  using  diazoxide,  exerts  a  protective  effect  on 
cardiac  cells,  neurons  in  the  brain  against  ischemic 
damage  and  death  in  experimental  models  of 
myocardial infarction (Baines et al., 1999; Murata et al., 
2001;  Takashi  et  al.,  1999;  Zaugg  et  al.,  2002)  and 
stroke(Lui  et  al.,  2002).  Additional  studies  have 
demonstrated  the  protective  role  of  diazoxide  on 
hypoxia-ischemia-reperfusion in cultured hippocampal 
neurons  and  gerbil  brain  (Wang  et  al.,  2011),  in 
cultured  hippocampal  and  cortical  neurons  against 
hypoxic and oxidative injury (Liu et al., 2003) and Aβ 
toxicity (Goodman and Mattson, 1996). In mice, using 
chronic  sublethal  hypoxia  as  a  model  of  PWMI,  we 
observed  that  diazoxide  markedly  reduces 
hypomyelination,  which  is  associated  with  PWMI 
(Fogal  et  al.,  2010).  Specifically,  we  observed,  that 
Oligodendrocyte Precursors (OPC) cultured in hypoxic 
conditions  had  reduced  OPC  proliferation  which  was 
reverse  with  diazoxide  by  stimulating  OPC 
proliferation (Fogal et al., 2010). 
These  observations  raise  the  possibilities  that 
diazoxide, currently approved for use in children by the 
FDA  as  a  treatment  for  hyperinsulinism,  may  have Michele M. Cox et al. / OnLine Journal of Biological Sciences 14 (1): 49-56, 2014 
 
50  Science Publications
 
OJBS 
potential  clinical  utility  in  other  aspects.  Diazoxide 
activates mitochondrial KATP (mitoKATP) channels that 
consist  of  two  structurally  diverse  subunits.  One 
subunit  is  a  member  of  the  pore-forming  inward 
rectifier Kir6.x family of potassium channels, while the 
other  subunit  is  a  Sulfonylurea  Receptor  (SUR)  that 
belongs  to  the  ATP-binding  cassette  superfamily 
(Babenko et al., 1998; 2000). 
By  employing  diazoxide  we  had  two  main 
objectives  in  this  study.  First,  we  thought  it 
worthwhile  to  investigate  the  long-term  effects  of 
neonatal  diazoxide  therapy  on  behavior  and 
morphology and 2) better elucidate the role of KATP 
channels on behavior and morphology. 
2. METHODS AND MATERIALS 
2.1 Animals 
All procedures related to animals were performed in 
accordance  with  Yale  University  Institutional  Animal 
Care  and  Use  Committee  and  University  Laboratory 
Animal Resources policies and guidelines. Adult male and 
female C57B/J6 mice were obtained from Charles River 
Laboratories  (Wilmington,  MA).  Mice  were  housed  in 
same sex cages and maintained in a temperature/humidity 
controlled room 12 h light/dark cycle. Mice had access to 
food  and  water  ad  libitum.  Timed  matings  were 
performed. Females were checked daily for the presence 
of  copulation  plugs.  Once  identified,  females  were 
separated from the males, the day vaginal plug was found 
designated as gestation day 0 (G) 0. 
Mice  were  weaned  at  postnatal  day  21  (P)  21. 
Behavioral testing was performed at 5-7 month of age 
because previous short-term studies demonstrated that 
chronic  diazoxide  therapy  did  not  cause  any 
behavioral  changes.  Animals  were  allowed  to 
acclimate to the testing room for approximately 1 h 
before  behavioral  testing  was  performed.  Animals 
were  naïve  to  behavioral  testing  prior  to  the  tests 
described.  The  investigator,  performed  behavioral 
tests was not aware of treatments. The present study 
was conducted on (2 treatments) ´ (2 genders) = (4 
groups) of 8-14 mice each. 
2.2 Drug Preparation and Administration 
Diazoxide (Tocris) was initially dissolved in dimethyl 
sulfoxide (DMSO; Sigma) to a final concentration of 20 
mg  mL
-1.  Stock  solution  (with  and  without  drug)  were 
diluted  in  Buffer  Saline  (D-PBS;  Invitrogen)  prior  to 
injection for drug and vehicle-control injections. C57B/J6 
pups were given a single injection daily in the nape of the 
neck with either vehicle or diazoxide (10, 20, 50 or 100 
mg kg
-1) from P2 to P12. This age period is equivalent to 
the vulnerable period of PWMI (Back and Rivkees, 2004; 
Craig et al., 2003). In preliminary studies, the dose of 100 
mg kg
-1 of diazoxide caused death in 84% of mice and 
therefore  was  not  used.  Individual  daily  doses  per  pup 
were based on the average litter weight per cage. 
2.3. Experimental Behavioral Procedures 
2.3.1. Physical and Neurological Screening 
The  physical  and  neurological  screening  tests 
performed  as  previously  described  (Cox  et  al.,  2009). 
Briefly, each mouse was weighed, placed in an empty 
cage  and  observed  for  3  min.  A  number  of  physical 
characteristics,  including  poor  grooming,  bald  spots, 
absence  of  whiskers,  labored  breathing  porphyrin 
staining,  were  characterized  and  recorded.  Several 
behavioral activities  were assessed including, jumping, 
sniffing,  rearing,  approach  to  object,  movement 
throughout  the  cage,  urination  and  defecation.  Visual 
acuity was assessed by placing each mouse on a visual 
cliff  platform  (28  cm  above  the  ground)  for  2  min. 
Behavioral  responses  such  as,  approach  to  edge  and 
poking nose over the edge were recorded. Sensorimotor 
reflexes (stabilization, righting, eye blink, ear touch and 
whisker  touch)  were  evaluated  and  recorded.  The 
animals’  behaviors  during  screenings  were  scored 
qualitatively in real time. In our previous we have not 
observed  hyperglycemia  in  comparably-treated  mice 
and therefore did not test hyperglycemia. In addition, 
a  key  symptom  of  hyperglycemia  is  increased  body 
weight, therefore body weights were measured before 
and after behavioral testing.  
2.3.2. Open Field Exploration 
Spontaneous  locomotor  activity  and  anxiety-like 
phenotypes  were  evaluated  using  the  open  field 
exploration  test,  as  described  previously  (Cox  et  al., 
2009). The Plexiglass chamber (28.2´28.2´27.2 cm) was 
cleaned before and between testing with 70% ethanol. A 
video camera was mounted directly above the apparatus. 
The  field  was  divided  into  two  regions  of  interest:  1) 
center  area  (5´5  cm)  and  2)  peripheral  area  (Noldus 
EthoVision  XT  version  8,  Wageningen,  The 
Netherlands). Two lamps with 60 W light bulbs were the 
only light sources in the room, providing an illumination 
intensity of 8 lux in the center of the open field. Mice 
were placed in the center of the open field and allowed to 
move freely for 12 min. The total distance traveled and Michele M. Cox et al. / OnLine Journal of Biological Sciences 14 (1): 49-56, 2014 
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the time spent in the brighter center (which tends to be 
aversive to mice) were recorded automatically using the 
Noldus  EthoVision  XT  tracking  system.  An  adverse 
effect  of  diazoxide  therapy  is  hypotension,  it  was  not 
possible  to  assess  blood  pressure  in  tmouse  pups  and 
therefore could not determine if mice had hypotension at 
the  time  of  drug  administration.  Hypotension  is 
associated  with  motor  deficits  which  were  measured 
using the open field exploration test. 
2.3.3. Rotarod 
Motor coordination/balance and  motor learning and 
memory  were  assessed  using  an  accelerating  rotarod 
(AccuScan  Instruments,  Inc.,  Columbus,  OH).  Mice 
were habituated as described (Cox et al., 2009) to the 
rotating rod at a constant speed of 4 rotations per minute 
(rpm) for 5 min, during which time latency to fall was 
not recorded. If a mouse fell off the apparatus, it  was 
quickly placed back on top of the rod until the 5 min trial 
was completed. The habituation trial was only performed 
on the first day. Mice were subsequently exposed to a 
rotating rod starting at 4 rpm and linearly accelerating to 
40 rpm over a period of 5 min. Mice were given three 
trials per day with a maximum time per trial of 5 min and 
30  min  inter-trial  rest  interval  for  5  consecutive  days. 
The  rotarod  was  cleaned  prior  to  testing  and  between 
animals  with  70%  ethanol.  If  a  mouse  reached  the 
latency  of  5  min  without  falling  the  trial  was  ended. 
Mice were tested at approximately the same time every 
day  for  5  consecutive  days  and  performances  in  daily 
trials were averaged for data analysis. 
2.3.4. Porsolt Forced Swim 
Depressive-like phenotypes were measured using the 
Porsolt  forced  swim  test,  as  described  (Porsolt  et  al., 
1977).  Mice  were  placed  in  cylindrical  beakers  filled 
with 10 cm of water for 5 min. The water temperature 
was between 21 and 24°C. A video camera was mounted 
directly above beaker to record mouse activity (Noldus 
EthoVision  XT  version  8,  Wageningen,  The 
Netherlands).  The  total  duration  of  immobility  (total 
amount of time animal is immobile during the 5 minute 
session) and latency to immobility (how much time it 
takes  before  the  animal  to  gives  up  searching  for  an 
escape  route)  were  recorded  automatically  using 
Noldus  EthoVision  XT  tracking  system.  Immobility 
was defined as the absence of movement, unless they 
are necessary for the animal to stay afloat (head above 
water).  After  testing,  mice  were  placed  on  warming 
mats before being returned to their cages. 
2.4. Behavioral Analysis 
Open  field  and  Porsolt  forced  swim  tests  were 
videotaped  using  an  Everfocus  EQ-610,  CDD  video 
camera  mounted  above  the  apparatuses  and  video 
tracked  using  Noldus  EthoVision  XT  version  8.  The 
system recorded total distance traveled and time spent in 
defined areas for the open field. For Porsolt forced swim 
test, total distance traveled, total duration of immobility 
and swim speed were recorded. Raw data were analyzed 
using  the  Noldus  EthoVision  XT  version  8  software 
(Noldus Information Technology). 
2.5. Histopathology 
After behavioral testing was completed, body weight 
was  measured  and  mice  were  euthanized  by  CO2 
inhalation. Calvarium was opened, brains weighed and 
immersed in Bouins’ solution. Brains were evaluated by 
Mouse Research Pathology laboratory in the Section of 
Comparative  Medicine  at  Yale  University.  Coronal 
sections were cut at 8 levels: (1) olfactory bulb, frontal 
and pyriform cortex; 2 and 3 septo-striatal (basal nuclei) 
to  septo-diencephalic;  4  and  5  rostral  to  caudal 
diencephalon (thalamus, hypothalamus, hippocampus); 5 
and  6  rostral  to  caudal  mesencephalon;  7  rostral 
cerebellum  and  brainstem;  (8)  caudal  cerebellum  and 
brainstem.  Sections  were  embedded  in  paraffin  for 
processing,  cut  at  5µm  and  stained  with  Hematoxylin 
and Eosin (H&E). Histologic sections were examined by 
light  microscopy  using  a  Zeiss  Axioscope  by  a 
pathologist masked to treatment.  
2.6. Statistical Analysis 
Data were analyzed using Graphpad Prism 5.0 for 
Windows (San Diego, CA). Normality of the data for 
each variable was determined using the D’Agostino and 
Pearson  test.  All  data  were  analyzed  using  one-way 
Analysis  of  Variance  (ANOVA)  followed  by  Sidak’s 
multiple  post  hoc  comparison  or  Kruskal-Wallis  test 
followed  by  Dunn’s  multiple  post  hoc  comparison. 
Rotarod  data  were  analyzed  using  two-way  ANOVA 
with  repeated  measure  followed  by  Bonferroni’s 
multiple  post  hoc  comparison.  All  data  presented  as 
mean ± SEM. For all analyses, statistical significance 
was defined as p≤0.05. 
3 RESULTS 
To assess the long term safety of diaoxide, C57B/J6 
pups  were  given  a  single  injection  daily  of  vehicle  or 
diazoxide (10, 20, or 50 mg kg
-1) from P2 to P12. Mice Michele M. Cox et al. / OnLine Journal of Biological Sciences 14 (1): 49-56, 2014 
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were weaned at P 21, behavioral tests were performed on 
both male and females at 5-7 months of age. 
3.1. Physical and Neurological Screening 
To  assess  neuromuscular  function,  sensori-motor 
function  and  visual  acuity,  mice  underwent  physical 
and  neurological  screenings.  No  qualitative 
differences in physical characteristics, visual acuity or 
sensori-motor  reflexes  were  observed  for  any 
treatment (10, 20 or 50 mg kg
-1). 
In  addition  to  the  above  tests,  body  weight  was 
examined.  Multiple  one-way  ANOVAs  or  Kruskal-
Wallis  tests  followed  by  post  hoc  multiple 
comparisons  revealed  a  no  significant  effect  of 
treatment on body weight for same sex animals. There 
was  significant  effect  of  gender  on  body  weight,  as 
females in all treatment groups had significantly lower 
weight than males as expected (10 mg kg
-1 treatment 
group  p  =  0.0074,  data  not  shown;  20  mg  kg
-1 
treatment  group  p<0.0001,  data  not  shown;  50  mg 
kg
-1 treatment groups p<0.0001, data not shown). 
3.2. Open Field Exploration 
To  measure  hyperactivity  and  general  spontaneous 
locomotor activity, total distance traveled was evaluated 
on  the  open  field  exploration  apparatus.  Kruskal-Wallis 
test  revealed  no  significant  effect  of  treatment  on 
locomotor activity for the 10 mg kg
-1 treatment group (p = 
0.0924; Table 1 and 2, respectively). Post hoc multiple 
comparison  did  not  show  any  significant  effect  of 
gender. One-way ANOVA demonstrated no statistically 
significant effect of treatment on locomotor activity in 
50  mg  kg
-1  treatment  group  (and  F[3,47]  =  1.692, p  = 
0.1815; Table 1 and 2, respectively). In addition, post 
hoc  comparison  revealed  no  significant  effect  of 
gender.  However,  the  Kruskal-Wallis  did  show 
significant  effect  of  treatment  for  the  20  mg  kg
-1 
treatment  group  (p  =  0.001).  Analysis  revealed  that 
diazoxide-treated  females  traveled  significantly  less 
than their vehicle-control counterparts Table 2. Similar 
results were not observed between vehicle-control and 
diazoxide-treated males Table 1. 
To  assess  anxiety-like  phenotypes  the  total  time 
spent  in  the  center  of  the  field  was  measured.  All 
treatment  groups  exhibited  a  clear  preference  for  the 
periphery of the open field chamber. One-way ANOVA 
and  Kruskal-Wallis  tests  demonstrated  no  significant 
effect of treatment on the total time spent in the center 
of open field for 10, 20 or 50 mg kg
-1 treatment groups 
(F[3,35] = 1.898, p = 0.1479, F[3,52] = 0.8159, p = 0.4190 
and  p  =  0.6380,  respectively;  Fig.  1)  In  addition, 
multiple comparison tests revealed no significant effect 
of gender on total time spent in the center of the open 
field for any treatment group. 
3.3. Rotarod 
To  assess  motor  coordination/balance  and  motor 
learning  and  memory,  mice  were  evaluated  on  an 
accelerating rotarod. The performance of 20 mg kg
-1 and 
50 mg kg
-1 treatment groups improved over the five days 
training. Two-way ANOVA with repeated measures of 
the  20  mg  kg
-1  treatment  group  showed  a  significant 
effect  of  gender  and  time  between  diazoxide-treated 
females and their male-counterparts only (F[1,34] = 33.26; 
p  =  0.0001  and  F  =  [4,136]  =  17.35;  p<0.0001, 
respectively). In addition, student t-test demonstrated a 
significant effect of treatment on performance between 
vehicle and diazoxide-treated females from day 3-day 5 
(p<0.05 Day 3, p<0.05 Day 4 and p<0.001 Day 5; Fig. 2. 
Similar results were not observed between vehicle and 
diazoxide-treated males. 
 Analyses  demonstrated  that  there  was  significant 
effect  of  time  between  vehicle-control  females  or 
diazoxide-treated  females  and  their  male-counterparts 
(F[4,100] = 21.54; p<0.001 and F[4,80] = 27.11; p<0.0001, 
respectively). Examination of the 50 mg kg
-1 treatment 
groups  revealed  a  significant  effect  of  gender,  with 
females performing better than their male counterparts 
(F[1,25]  =  2003;  p  =  0.0001  (vehicle)  and  F  =  [1,20]  = 
6.240; p = 0.0213 (diazoxide). In addition, student’s t-
test  revealed  a  significant  effect  of  treatment  on 
performance  between  vehicle  and  diazoxide-treated 
females  on  the  final  day  of  testing  (p<0.05;  Fig.  3. 
Similar results were not observed between vehicle and 
diazoxide-treated males. 
3.4. Porsolt Forced Swim 
To evaluate depressive-like phenotypes duration of 
immobility was evaluated on the Porsolt forced swim 
apparatus.  Analysis  duration  of  immobility  using 
Kruskal-Wallis  and  one-way  ANOVA  revealed  no 
significant effect of treatment for 20 or 50 mg kg
-1 (p 
= 0.2162 and F[3,47] = 0.1908, p = 0.9022, respectively; 
Fig. 4. One-way ANOVA demonstrated a significant 
effect of treatment on duration to immobility from the 
10  mg  kg
-1  treatment  group  was  shown  (F[3,36]  = 
4.434,  p  =  0.0094.  Post  hoc  multiple  comparison 
analysis  showed  that  diazoxide-treated  females  had 
longer duration of immobility than their vehicle-control 
counterparts (p<0.05. Similar results were not observed 
for  between  diazoxide-treated  males  and  their  vehicle-
control  counterparts.  Analysis  also  revealed  no 
significant effect of gender for any treatment group. Michele M. Cox et al. / OnLine Journal of Biological Sciences 14 (1): 49-56, 2014 
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Fig. 1. Open field exploration total time spent in center: Total time (s) spent in the center of the open field during twelve minute 
session for vehicle Vs. diazoxide at all treatments (top; Female (F) and bottom; male). Analyses performed using one-way 
ANOVA or Kruskal-Wallis test. (10 mg kg
-1 n = 8 vehicle (F), n = 8 vehicle (M), n = 10 diazoxide (F) and n = 13 diazoxide 
(M); 20 mg kg
-1 n = 11 vehicle (F), n = 9 vehicle (M), n = 17 diazoxide (F) and n = 19 diazoxide (M); 50 mg kg
-1 n = 14 
vehicle (F), n = 13 vehicle (M), n = 14 diaozixde (F) and n = 10 diazoxide (M)). 
 
   
 
Fig. 2. Rotarod Performance Daily Latencies to Fall: Improvement in the latency to fall as mice managed to stay atop accelerating 
rotarod over 5 consecutive days with 3 trials per day for vehicle Vs. diazoxide (20 mg kg
-1) (top) Female (F) and (bottom) 
Male (M). Analyses performed using multiple two-way ANOVA with repeated measures. [n = 11 vehicle (F), n = 9 vehicle 
(M), n=17 diazoxide (F) and n = 19 diazoxide (M); *p<0.05 
 
   
 
Fig. 3. Rotarod performance daily latencies to fall: Improvement in the latency to fall as mice managed to stay atop accelerating rotarod 
over 5 consecutive days with 3 trials per day for vehicle Vs. diazoxide (50 mg kg
-1) (top) female (F) and (bottom) male (M). 
Analyses performed using multiple two-way ANOVA with repeated measures and student t test for individual daily comparisons. 
[50 mg kg
-1 n = 14 vehicle (F), n = 13 vehicle (M), n = 14 diaozixde (F) and n = 10 diazoxide (M)]. *p<0.05, **p<0.001 Michele M. Cox et al. / OnLine Journal of Biological Sciences 14 (1): 49-56, 2014 
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Fig. 4. Porsolt forced swim total duration of immobility: Total duration mice were immobile in (s) during 5 min session. Analyses 
performed using Kruskall-Wallis or one-way ANOVA tests. (10 mg kg
-1 n = 8 vehicle (F), n = 8 vehicle (M), n = 10 
diazoxide (F) and n = 13 diazoxide (M); 20 mg kg
-1 n = 11 vehicle (F), n = 9 vehicle (M), n = 17 diazoxide (F) and n = 19 
diazoxide (M); 50 mg kg
-1  n = 14 vehicle (F), n = 13 vehicle (M), n = 14 diaozixde (F) and n = 10 diazoxide (M)). 
 
Table 1. Total distance traveled in the open field during welve 
minute session (Males) 
Treatment  Gender  Distance traveled (m) 
Vehicle   Male  24.41±1.770 
Diazoxide 
(10 mg kg
-1)  Male  28.02±0.9244 
Vehicle  Male  23.97±2.868 
Diazoxide  
(20 mg kg
-1)  Male  26.08±1.348 
Vehicle  Male  20.51±1.411 
Diazoxide 
(50 mg kg
-1)  Male  21.59±1.866 
Note.  Distance traveled values presented as mean ± SE in meters 
(m).  No significant differences were observed between treatment 
groups.  Analyses performed using Kruskal-Wallis and one-way 
ANOVA tests. (10 mg kg
-1 n = 8 vehicle and n = 13 diazoxide; 20 
mg kg
-1 n = 9 vehicle and n = 19 diazoxide; 50 mg kg
-1 n = 13 
vehicle and n = 10 diazoxide) 
 
3.5. Histopathology 
H&E  stained  sections  of  brains  from  all  treatment 
groups provided no evidence of significant histological 
lesion(s) present for vehicle or diazoxide-treated mice at 
any level examined (data not shown). In addition,  final 
body  weight  measurements  were  performed.  Analyses 
revealed no significant effect of treatment on body weight 
of same sex animals for any treatment group. In 10 mg 
kg
-1 treatment group p = 0.8260 (females) and p = 0.0780 
(males) (data not shown). For the 20 mg kg
-1 treatment 
group p = 0.0511 (females) and p = 0.3731 (males; data 
not shown). The 50 mg kg
-1 treatment groups p = 0.0998 
(female) p = 0.1714 (males; data not shown). 
Table 2. Total distance traveled in the open field during twelve 
minute session (Females) 
Treatment  Gender  Distance traveled (m) 
Vehicle  Female  28.94±2.359 
Diazoxide 
(10 mg kg
-1)  Female  30.50±1.663 
Vehicle  Female  39.17±2.275 
Diazoxide 
(20 mg kg
-1)  Female  30.34±1.524*** 
Vehicle  Female  23.66±2.127 
Diazoxide 
(50 mg kg
-1)  Female  26.57±2.534 
Note.  Distance traveled values presented as mean ± SE in 
meters (m).  Significant observed in the 20 mg kg
-1 treatment 
group  ***p<0.001.  Analyses performed using Kruskal-Wallis 
and one-way ANOVA tests. (10 mg kg
-1 n = 8 vehicle and n = 
10 diazoxide; 20 mg kg
-1 n = 11 vehicle and n = 17 diazoxide; 50 
mg kg
-1 n = 14 vehicle and n = 14 diazoxide) 
 
4. DISCUSSION 
This study demonstrates for the first time the long 
term effect of .chronic neonatal diazoxide therapy. In 
this  study  we  provide  evidence  that  chronic  neonatal 
administration  of  diazoxide did  not  contribute  to  any 
changes in physical appearance, sensori-motor skills or 
working memory. In neuropathological studies, we did 
not observe any brain abnormalities in any of the mice 
treated  in  the  neonatal  period  and  examined  in 
adulthood.  We  recognize  that  only  hematoxylin  and 
eosin was used to stain tissue sections. However, this Michele M. Cox et al. / OnLine Journal of Biological Sciences 14 (1): 49-56, 2014 
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method is a well-recognized neuropathological staining 
technique and examining thousands of tissue sections, 
no defects were observed. We also recognize that it is 
not  possible  to  differentiate  whether  the  lack  of 
neuroantatomical  defects,  or  motor  impairments  are 
due to an absence of toxic effects of the treatment or a 
natural  regeneration  of  the  mice.  It  is  important  to 
note that in our in our previous short-term studies, we 
did  not  observe  any  structural  brain  abnormalities 
(Fogal  et  al.,  2010).  Furthermore,  behavioral  tests 
cannot be performed until 9-12 weeks after treatment 
precluding early testing. 
In  our  experimental  conditions,  diazoxide-treated 
mice  did  not  travel  significantly  greater  distances  or 
show a significant difference in their preference for the 
periphery  compare  to  their  vehicle  counterparts  in  the 
open  field.  Consequently,  we  can  conclude  that 
diazoxide did not cause modification(s) in spontaneous 
locomotor activity such as hyperactivity or anxiety-like 
phenotype.  Similarly,  no  significant  differences  were 
detectable  in  motor  coordination  and  working  memory 
between  diazoxide  treated  mice  and  their  control-
counterparts  on  the  rotarod.  Interestingly,  females 
demonstrated better perform on the rotarod, similar results 
have been shown in another mice strain (Cox et al., 2009). 
Additionally, we observed that female mice treated with 
20 mg kg
-1 of diazoxide had better motor coordination 
and  balance  than  their  vehicle-control  counterparts. 
Hyperactivity can not reflect the results exhibited in the 
rotarod  as  no  hyperactivity  was  recorded  in  the  open 
field exploration test. Similar results were not observed 
with  the  50  mg  kg
-1  group;  in  fact  we  see  that  the 
vehicle-treated  females  performed  better  than  their 
diazoxide-treated  counterparts.  Suggesting  that  a 
threshold  was  reach  in  which  the  addition  of  more 
diazoxide did not continue to increase performance. 
Diazoxide  did  not  appear  to  enhance  or  inhibit 
swimming abilities or the motivation to escape the water 
in the Porsolt forced swim test. We demonstrated that 
chronic  neonatal  administration  of  diazoxide 
significantly  increased  duration  of  immobility  in 
diazoxide-treated  females  (10  mg  kg
-1).  These  results 
provide evidence for the involvement of KATP channels in 
the  induction  of  depressive-like  phenotype.  Our  results 
correlate with previous studies that demonstrated this anti-
immobility effect of various KATP channel openers in the 
forced  swim  test  (Galeotti  et  al.,  1999;  Redrobe  et  al., 
1996).  In  addition,  our  data  is  the  first  to  illustrate 
gender-specific involvement of KATP channel openers 
influence on immobility. Taken as a whole, our results 
would suggest that KATP channels functionally appear 
to  be  fundamental  in  the  modulation  of  motor 
coordination and immobility. 
The  observed  depressive-like  phenotype  may 
reflect  the  hypothesis  that  KATP  channel  openers 
cause  hyperpolarization  of  neurons.  One  study 
revealed  that  KATP  channel  opener,  diazoxide 
effectively  depressed  the  excitability  of  the  CA1 
interneuron (Griesemer et al., 2002). In addition, this 
study  showed  that  diazoxide  altered  the  resting 
membrane potential producing hyperpolarization in three 
types of hippocampal neurons (Griesemer et al., 2002). 
However, diazoxide had no effect on the amplitude of 
the action potential (Griesemer et al., 2002). Therefore 
one  may  conclude  that  the  reason  for  the  depressive 
effects  we  observed  by  the  chronic  neonatal 
administration of diazoxide is because the neurons have 
a more negative resting membrane potential. 
5. CONCLUSION 
In  summary,  we  find  that  chronic  neonatal 
diazoxide therapy does not enhance or cause long term 
deficits  to  neurological  functions,  motor  function  or 
learning  and  memory  enhancements  in  mouse 
behavior. However, diazoxide may induce depressive-
like phenotypes in females. Diazoxide does not cause 
changes in gross anatomy and histology of the brain. 
As  such,  these  studies  provide  important  preclinical 
data for potential future studies aimed at assessing the 
potential clinical utility of diazoxide. 
6. ACKNOWLEDGEMENT 
This  research  was  supported  in  part  from  grants 
from  National  Institute  of  Health  (3R01NS068039-
02S1) and National Institute of Neurological Disorders 
and Stroke (S068039). Some of the data from the paper 
were previously presented at the annual meeting of the 
Society  for  Neuroscience  in  New  Orleans  (October 
2012). Authors do not have any interests that might be 
interpreted as influencing the research and APA ethical 
standards were followed in conducting the study. It is a 
pleasure  to  thank  Sarah  Renzi  for  her  technical 
assistance with this study. 
7. REFERENCES 
Ashcroft, S.J. and F.M. Ashcroft, 1990. Properties and 
functions of ATP-sensitive K-channels. Cell Single,   
2:197-214. PMID: 2119205 Michele M. Cox et al. / OnLine Journal of Biological Sciences 14 (1): 49-56, 2014 
 
56  Science Publications
 
OJBS 
Babenko, A.P., L., Aguilar-Bryan and J. Bryan, 1998. A 
view of SUR/KIR6.X, KATP channels. Annual Rev. 
Physiol.,  60:  667-687.  DOI: 
10.1146/annurev.physiol.60.1.667 
Babenko,  A.P.,  G.  Gonzalez  and  J.  Bryan,  2000. 
Pharmaco-topology  of  sulfonylurea  receptors: 
Separate domanins of the regulatory subunits of K 
channel  is  forms  are  required  for  selective 
interaction with K+ channel openers. J. Biol. Chem., 
275: 717-720. DOI: 10.1074/jbc.275.2.717 
Back, S.A. and S.A. Rivkees, 2004. Emerging concepts 
in  periventricular  white  matter  injury.  Seminars 
Perinatol.,  28:  405-414.  DOI: 
10.1053/j.semperi.2004.10.010 
Baines, C.P., G.S. Liu, M. Birincioglu, Critz and S.D., 
Cohen  et  al.,  1999.  Ischemic  preconditioning 
depends  on  interaction  between  mitochondrial 
KATP  channels  and  actin  cytoskeleton.  Am.  J. 
Physiol., 276: H1361-1368.  
Cox, M.M., A.M. Tucker, J. Tang, K. Talbot and D.C. 
Richer et al., 2009. Neurobehavioral abnormalities 
in  the  dysbindin-1  mutant,  sandy,  on  a  genetic 
background. Genes, Brain Behav., 8: 390-397. DOI: 
10.1111/j.1601-183X.2009.00477.x 
Craig, A., N.L. Luo, D.J Beardsley, N., Wingate-Pearse 
and  D.W.  Walker,  2003.  Quantitative  analysis  of 
perinatal rodent oligodendrocyte lineage progression 
and its correlation with human. Exp. Neurol., 181: 
231-240. PMID: 12781996 
Fogal,  B.,  C.  McClaskey,  S.  Yan,  H.  Yan  and  S.A. 
Rivkees, 2010. Diazoxide promotes oligodendrocyte 
precursor  cell  proliferation  and  myelination.  Plos 
One,  5:  E10906-E10906.  DOI: 
10.1371/journal.pone.0010906 
Galeotti, N., C. Ghelardini, B. Caldari and A. Bartolini, 
1999.  Effect  of  potassium  channel  modulators  in 
mouse forced swimming test. British J. Pharmacol., 
126: 1653-1659. DOI: 10.1038/sj.bjp.0702467 
Goodman,  Y.  and  M.P.  Mattson,  1996.  K+  channel 
openers  protect  hippocampal  neurons  against 
oxidative injury and amyloid beta-peptide toxicity. 
Brain  Res.,  706:  328-332.  DOI:  10.1016/0006-
8993(95)01367-9 
Griesemer, D., C. Zawar and B. Neumcke, 2002. Cell-
type specific depression of neuronal excitability in 
rat  hippocampus  by  activation  of  ATP-sensitive 
potassium channels. Eur. Biophys., J. 31: 467-477. 
DOI: 10.1007/s00249-002-0241-3 
Liu, D., J.R. Slevin, C. Lu, S.L. Chan and M. Hansson et 
al., 2003. Involvement of mitochondrial K+ release 
and  cellular  efflux  in  ischemic  and  apoptotic 
neuronal death. J. Neurochem., 86: 966-979. PMID: 
12887694 
Lui,  C.Y.,  F.I  Marcus  and  R.E  Sobonya,  2002. 
Arrhythmogenic  right  ventricular  dysplasia 
masquerading  as  peripartum  cardiomyopathy  with 
atrial  flutter,  advanced  atrioventricular  block  and 
embolic  stroke.  Cardiology,  97:  49-50.  DOI: 
10.1159/000047419 
Murata, M., M. Akao, B. O’Rourke and E. Marban, 2001. 
Mitochondrial  ATP-sensitive  potassium  channels 
attenuate matrix Ca (2+) overload during simulated 
ischemia  and  reperfusion:  Possible  mechanism  of 
cardioprotection.  Circ.  Res.,  89:  891-898.  PMID: 
11701616  
Porsolt, R.D., A. Bertin and M. Jalfre, 1977. Behavioral 
despair  in  mice:  A  primary  screening  test  for 
antidepressants. Archives Int. de pharmacodynamie 
et de therapie, 229: 327-336. PMID: 596982 
Redrobe, J.P., P. Pinot and M. Bourin, 1996. The effect 
of the potassium channel activator, cromakalim, on 
antidepressant drugs in the forced swimming test in 
mice. Fundamental Clin. Pharmacol., 10: 524-528. 
DOI: 10.1111/j.1472-8206.1996.tb00610.x 
Takashi, E., Y. Wang and M. Ashraf, 1999. Activation of 
mitochondrial  K  (ATP)  channel  elicits  late 
preconditioning  against  myocardial  infarction  via 
protein kinase C signaling pathway. Circ. Res., 85: 
1146-1153. DOI: 10.1161/01.RES.85.12.1146 
Wang, L., Q.L. Zhu, G.Z. Wang, T.Z. Deng and R. Chen 
et al., 2011. The protective roles of mitochondrial 
ATP-sensitive potassium channels during hypoxia-
ischemia-reperfusion in brain. Neurosci. Lett., 491: 
63-67. DOI: 10.1016/j.neulet.2010.12.065 
Zaugg, M., E. Lucchinetti, D.R. Spahn, T. Pasch and C. 
Garcia  et  al.,  2002.  Differential  effects  of 
anesthetics  on  mitochondrial  K  (ATP)  channel 
activity  and  cardiomyocyte  protection. 
Anesthesiology,  97:  15-23.  DOI: 
10.1097/00000542-200207000-00004 